232 results
Page 3 of 12
8-K
EX-99.1
bpsbgw 1oe13pfp
13 Jun 23
Other Events
8:25am
8-K
EX-99.1
zgnn3mqhg0hgxx3w0t
12 May 23
Departure of Directors or Certain Officers
8:13am
8-K
EX-99.1
rb95k vbe
2 May 23
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH
8:18am
8-K
EX-99.1
74p2nr9wirv7uwwh7
3 Apr 23
NeuroBo Pharmaceuticals Announces Submission of IND Application to the FDA for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH
8:14am
8-K
EX-99.1
30kw eocz
30 Mar 23
NeuroBo Pharmaceuticals Reports Full Year 2022 Financial Results
4:47pm
8-K
EX-10.2
toahi0
22 Dec 22
Departure of Directors or Certain Officers
5:08pm
8-K
EX-10.1
9i4 wzmsf
22 Dec 22
Departure of Directors or Certain Officers
5:08pm
8-K
EX-4.5
zusio2u4ib919
8 Nov 22
Neurobo Announces Pricing of $30 Million Underwritten Public Offering and Concurrent Private Placement
5:24pm
8-K
EX-4.2
spclvnq
8 Nov 22
Neurobo Announces Pricing of $30 Million Underwritten Public Offering and Concurrent Private Placement
5:24pm
8-K
EX-1.1
nntw6aha30d
8 Nov 22
Neurobo Announces Pricing of $30 Million Underwritten Public Offering and Concurrent Private Placement
5:24pm
8-K
EX-4.4
cglw dcokvoj2n4xxa
8 Nov 22
Neurobo Announces Pricing of $30 Million Underwritten Public Offering and Concurrent Private Placement
5:24pm
8-K
EX-99.1
sogbf1l7h70lly8l
8 Nov 22
Neurobo Announces Pricing of $30 Million Underwritten Public Offering and Concurrent Private Placement
5:24pm